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Abstract 
Introduction and aims: Prescribing of lipid lowering agents (LLAs) has increased worldwide including in 
Scotland with increasing prevalence of coronary heart disease, and higher dose statins have been 
advocated in recent years. There have also been initiatives to encourage prescribing of generic versus 
patented statins to save costs without compromising care. There is a need to document these 
initiatives and outcomes to provide future direction. Method: Assessment of utilization (items 
dispensed) and expenditure of key LLAs (mainly statins) and expenditure between 2001 and 2015 in 
Scotland alongside initiatives. Results: Multiple interventions have increased international non-
proprietary name (INN) prescribing (99% for statins) and preferential prescribing of generic versus 
patented statins, and reduced inappropriate prescribing of ezetimibe. This resulted in a 50% reduction 
in LLA expenditure between 2001 and 2015 despite a 412% increase in utilization, increased 
prescribing of higher dose statins (71% in 2015) especially atorvastatin following generic availability, 
and reduced prescribing of ezetimibe (reduced by 72% between 2010 and 2015). As a result, the 
quality of prescribing has improved. Conclusion: Generic availability coupled with multiple measures 
has resulted in appreciable shifts in statin prescribing behavior and reducing ezetimibe prescribing, 
resulting in improvements in both the quality and efficiency of prescribing.  
 
1. Introduction 
 
As a result of the increasing prevalence of chronic diseases across countries due to ageing 
populations, cardiovascular diseases have become the leading cause of death worldwide including 
Europe (1, 2). In response to this trend, lipid lowering agents (LLA), mainly statins, have become one 
of the most prescribed medicines in developed countries, with increasing use in lower and middle 
income countries although at lower rates (3-7). This is because statins have proved to be both 
effective and safe in both primary and secondary prevention of cardiovascular events, as well as 
improve survival in patients with coronary heart disease (8-12).  
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Currently over half the adults in the UK have raised cholesterol (>5mmol/ l)  (13). As a result, many 
patients are at risk of developing coronary heart disease (CHD), cerebrovascular disease, and 
peripheral vascular disease unless adequately treated (14). Studies have shown that patients with 
dyslipidemias benefit from an intensive treatment with lipid lowering therapies for both primary, 
secondary and tertiary prevention of cardiovascular disease (15-17). The National Health Service 
(NHS) of Scotland, which provides universal healthcare for its citizens including no co-payment for 
medicines, spent over GB£23 million in 2015 alone on LLAs, with the objective of decreasing 
cardiovascular morbidity and mortality among its population. This  represented just over 2% of the total 
budget for medicines and appliances dispensed in 2015 at GB£1017.6billion (18).  
 
To maximize the cost-effectiveness of using LLAs in the face of continuing resource pressures 
associated with changing demographics and funding new premium priced medicines, the Scottish 
government combined with the Health Boards have introduced a range of measures to enhance 
prescribing efficiency. Scotland currently has 14 Health Boards with devolved budgets that manage 
patients within their region. Ongoing initiatives include promoting international non-proprietary (INN) 
prescribing starting in medical schools and continued in practice-settings with education and IT 
support systems (19, 20). This is particularly important in the UK as pharmacists are not allowed to 
substitute an originator for a generic if the physician prescribes the originator (21). This is unlike 
Sweden where there is compulsory generic substitution and Lithuania where there is compulsory INN 
prescribing (22, 23). Acceptance of INN prescribing in the UK in this situation is facilitated by studies 
showing no difference in effectiveness between generic and originator statins (24, 25). However, we 
are aware that there are still European countries where physicians have concerns with generics (26-
29). Potential savings in the UK from generic statins are enhanced by prices as low as 3% of pre-
patent loss originator prices (19, 20). Low prices for generics in the UK are aided by the introduction of 
the ‘M’ and ‘W’ scheme (Manufacturer and Wholesaler) in April 2005. The scheme was introduced to 
enhance transparency in the prices of generics, including any rebates, and is based on quarterly 
surveys of transaction prices between manufacturers, wholesalers, and pharmacists in the UK (19). 
Prior to this, prices of generics were less transparent with generic manufacturers offering discounts up 
to 80% or more on their list prices to community pharmacists to increase their volumes (19), with the 
NHS typically paying the full list price. Other activities include measures to enhance the prescribing of 
low cost generic statins first line once available rather than appreciably higher cost patented statins, 
with all statins initially seen as similar at therapeutic doses (20). These combined measures have 
resulted in considerable savings (20). This is different to countries where there have been limited 
demand side measures to encourage the prescribing of generic statins first line, which have resulted in 
expenditure on statins up to ten times greater when adjusted for population size (30). Switching to 
preferentially prescribing generic statins has not compromised care (31-33). A similar situation has 
also been seen in other product classes across Europe including the proton pump inhibitors and the 
renin-angiotensin inhibitors (30, 34, 35).  
 
Recent initiatives in Scotland to improve the quality of prescribing include advocating the prescribing of 
higher doses of statins. This is based on recommendations to physicians from SIGN (Scottish 
Intercollegiate Guidelines Network), which is the national guidelines group in Scotland, to prescribe 
higher dose statins, e.g. 40mg simvastatin, following publications such as the Heart Protection Study 
(10, 20).  In addition, the instigation of quality standards, the Quality and Outcome Framework (QoF), 
linked with financial incentives to meet agreed quality targets, with data collated by ISD in Scotland 
(19, 20, 36). The quality target goals included the following for patients with hypercholerterolaemia; (i) 
the percentage of patients with CHD whose last measured total cholesterol (measured in the last 15 
months) is 5mmol/l or less; (ii) the percentage of patients with a TIA or stroke whose last measured 
total cholesterol (measured in the last 15 months) is 5mmol/l or less and (iii) the percentage of patients 
with diabetes whose last measured total cholesterol within previous 15 months is 5 or less (19, 20). 
More recently in Scotland high dose statins, e.g. 80mg atorvastatin, have been advocated in patients 
with establish coronary vascular disease (37).  High dose atorvastatin is increasingly advocated 
because of safety concerns with high dose simvastatin, enhanced by generic atorvastatin availability 
(11).  
 
We wish to add to our original research following the availability of generic atorvastatin, greater 
endorsement of the prescribing of high dose statins as well as growing concerns with the 
appropriateness of prescribing of ezetimibe due to issues with its effectiveness in reducing cardiac 
events compared with statins (38-41). We are aware that studies have been published advocating the 
prescribing of higher dose statins; however, we are unaware of European countries formally 
introducing quality targets based on lipid levels linked with financial incentives alongside the 
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publications as seen in the UK. As a result even in Stockholm County Council, Sweden, with 
considerable activities to enhance the quality and efficiency of prescribing in ambulatory care, 
including financial incentives for GPs (23, 42-44), the average dispensed dose of simvastatin was only 
20.4mg in 2008, with 35% of prescriptions as 10mg and only 25% as higher strength simvastatin (20).  
In addition, only a limited number of European countries have introduced initiatives to enhance 
appropriate prescribing of ezetimibe (41).  
 
In this paper, we will ascertain the effects of ongoing activities among the Health Boards in Scotland to 
improve efficient prescribing of LLAs to take advantage of the availability of generic atorvastatin and 
simvastatin. Our analysis will shed light on both the scale of the potential patient benefit which can be 
realized through the use of LLAs as well as the influence of changing prices on the prescribing mix. 
We are aware that there have been many published studies that have investigated the influence of 
different approaches either singly such as prescribing restrictions or combined initiatives across 
Europe to enhance the prescribing of generic versus patented LLAs (7, 30, 35, 45-50). However, we 
believe this is the first time that such a comprehensive analysis has been undertaken in a European 
country combining multiple initiatives to improve both the quality and efficiency of prescribing of LLAs. 
 
This builds on our previous publications regarding policies to influence the prescribing generic statins 
in Scotland (20, 34).  
 
2. Methodology 
 
2.1 Uilisation and expenditure data 
To evaluate the utilisation and prescribing patterns of  LLA in Scotland, the prescription costs analysis 
(PCA) database compiled by the Information Services Division (ISD) of NHS Scotland was analysed 
from 2001 to 2015 (18). NHS Scotland is a universal service which serves the entire resident 
population of Scotland (20). There is currently no co-payment for medicines in Scotland. 
 
PCA contains information on all prescriptions being dispensed in the community setting in Scotland. 
Only drugs categorized as “Lipid-Regulating Drugs” by the British National Formulary (BNF) 
(https://www.bnf.org/products/bnf-online/), and which were simultaneously dispensed by NHS 
Scotland, were considered initially to be eligible for inclusion in this study. Many studies have shown 
that statins and inhibitors of the cholesterol-absorption are more effective, safe, and better tolerated, in 
comparison to other classes of LLAs (9, 10, 51-53), and the prescribing of bile acid sequestrants, 
fibrates, derivatives of nicotinic acid, derivatives of niacin, and derivatives of omega-3 fatty acids, have 
greatly reduced in the past decades. As a result, these classes of LLAs were not included in this study. 
Furthermore, in 2015, this group of LLAs represented just 1.6% of total LLA units dispensed by the 
Scottish NHS.  
 
Between 2001 and 2015, the Scottish NHS made 16 different types of LLAs available to be 
prescribed; however, because of the aforementioned reasons, only seven LLAs are included in this 
study. They comprise five different statins, i.e. atorvastatin, rosuvastatin, pravastatin, simvastatin and 
fluvastatin, one selective cholesterol-absorption inhibitor (ezetimibe) and one combination product 
(simvastatin/ezetimibe). 
 
From each medicine included in this study, the following information was extracted from the PCA 
between 2001 and 2015: generic name, commercial name(s), formulation(s), drug strength(s), number 
of dispensed units, cost per unit and total gross expenditure. All costs are depicted in Great Britain 
pounds (GB£s). No adjustment for inflation for the prices was made. This is in line with previous 
studies, due to the rapid reduction in prices once statins became available as generics (20, 30, 34).  
 
Whilst NHS Scotland routinely uses defined daily doses (DDDs) when presenting and discussing 
utilization data in line with international guidance (54, 55), we used items dispensed. This is because 
we wanted to track actual prescriptions, especially with physicians being encouraged to prescribe 
higher strength statins as well as reduce their prescribing of ezetimibe alone or in combination. In the 
case of patients with chronic diseases such as hypercholesterolemia, a prescription in terms of ‘items 
dispensed’ is usually for 28 or 56 days. However, there has been a tendency in recent years for 
physicians to increase the length of a prescription to help with their growing workloads. We recognize 
that using ‘items dispensed’ will impact on any analysis of prescribed volumes when compared with 
DDDs, especially when physician prescribing higher doses, as well as make comparisons across 
countries difficult. However, our primary aim was an evaluation of prescribing practices.  
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For each LLA and year, the total costs, items dispensed and expenditure proportion they represent to 
the NHS were calculated. In addition, a sub-analysis of the prescription costs for generic and patented 
presentations of each LLA was estimated. This information was plotted over time in years, and used to 
compare all generics and originators of one particular LLA. The date at which the each LLA became 
generically available in Scotland was obtained from an internal NHS database. In addition to the loss 
of patent, other interventions were considered and analyzed. We did not adjust prices according to 
inflation as the tendency is for medicine prices to appreciably reduce rather than increase, especially 
once generics are available. This is similar to previous published analyses assessing the influence of 
policies to encourage the prescribing of low cost generics versus patented statins (7, 19, 20, 30, 41, 
49, 50). 
 
2.2 Demand-side measures 
Accordingly, the ongoing activities within the Health Boards and NHS Scotland to improve the 
efficiency of LLA prescribing were collated using the 4E methodology, building on previous findings: 
Education, Engineering, Economics and Enforcement (20, 34, 56). Education refers to initiatives such 
as guidelines and academic detailing; engineering refers to organizational or managerial interventions 
such as prescribing indicators; economics to financial incentives for prescription; and enforcement 
refers to regulations from health authorities (34, 56). NHS Scotland initiatives incorporate both 
education including SIGN guidelines for patients with coronary vascular diseases including diabetes as 
well as national prescribing indicators including the percentage of statins prescribed as generics 
versus patented statins, the extent of prescribing of ezetimibe versus other LLAs as well as lipid level 
targets for patients with hypercholesterolaemia  (20, 37, 54) (Table 2, Figure 2).   
 
We did not undertake any time-series analyses as multiple interventions inter-linked activities were 
undertaken at different times both nationally and regionally between 2001 and 2015. Consequently, it 
was impossible to select just one intervention or interventions to concentrate on at one time point to 
the exclusion of others. 
 
3. Results 
 
3.1 Generic availability of LLAs 
Of the 7 different types of LLAs that were included in this study, none were generically available in 
2001. Furthermore 27 different formulations and strengths of all LLAs (including generic and patented) 
were available at NHS Scotland in the year 2001. By 2015, 4 out of 7 (57.1%) LLAs were generically 
available and the availability of different formulations and strengths had doubled, with 56 different 
combinations (Table 1). 
 
Table 1 - Lipid lowering agents included in this study and patent expiration date in Scotland from 2001 
to 2015 
Generic Name Commercial Name 
Number of 
Formulations and 
Strengths 
Year of 
patent 
expiration 
Atorvastatin Lipitor®  14 2012 
Ezetimibe Ezetrol® 2 2017 
Ezetimibe/simvastatin Inegy® 3 2019 
Fluvastatin 
Dorosin XL® 
9 2008 
Lescol® 
Luvinista PR®  
Pinmactil MR® 
Pravastatin Lipostat® 6 2004 
Rosuvastatin Crestor® 8 2017 
Simvastatin 
Simvador® 
14 2003 Ranzolont® 
Zocor® 
NB: The commercial name includes the originator and any parallel imports 
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3.2 Total utilisation and expenditure 
A steady increase in the number of total items dispensed was observed between 2001 and 2015 for 
the seven LLAs of interest. 1.212 million items were dispensed in 2001 with an associated cost of 
GB£43.39 million, rising to 4.99 million units in 2015 at a cost of GB£21.77 million. This represents an 
increase of 412.1% in the prescription rate but a decrease of 50.2% in overall costs during the past 14 
years due to increasing use of low cost generics. In 2001, LLA expenditure represented 6.82% of the 
total NHS budget for medications, but by 2015, this was reduced to 2.34% enhanced by generic 
availability (Figure 1).  
 
Figure 1 - Total expenditure of selected LLAs between 2001 and 2015  
 
 
 
Even though the loss of patents has a meaningful impact on the prescription rate (items dispensed) 
and the costs associated with it, they do not constitute the only explanations for the trends observed 
with LLAs in Scotland.  
 
3.3 Demand-side measures 
Multiple reforms and initiatives were introduced in the UK to enhance the prescription and use of low-
cost generic drugs. As mentioned, the introduction of the “M” (manufacturer) and “W” (wholesaler) 
scheme in April 2005 led to an average reduction of 32.4% in the prices of generics (19, 34, 57, 58), 
with prices falling still further. The inclusion of lipid level targets in the Quality and Outcomes (QoF) 
Framework since 2003 (target of <5 mmol/l)  (20, 59), and the development of the Scottish 
Intercollegiate Guidelines Network (SIGN Guideline) (60) for the risk estimation and the prevention of 
CVD, which advocated high doses of simvastatin (40 mg/day) in adults with high risk for a 
cardiovascular event, led to an increase in their prescribing and doses. Table 2 contains a summary of 
measures that were introduced in Scotland by the Health Boards and nationally since 2001 to increase 
and efficiently use LLAs while simultaneously reducing costs over the years, with Figure 2 providing a 
timeline of major events. 
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Table 2 - Summary of principal demand-side measures introduced in Scotland between 2001 and 
2015 that influenced the consumption of lipid lowering agents [Adapted from (20, 30, 34, 54, 59-67)]  
 
Measure Year National or 
Regional 
Initiative 
Education 
2001 - 
2007 
National and 
Regional 
 Physicians typically trained in medical school to 
prescribe by INN name with follow up in the community 
coupled with IT systems to enhance INN prescribing 
 National guidance and guidelines (SIGN) for primary and 
secondary prevention with statins including patients with 
diabetes, with higher doses of statins (e.g. 40mg 
simvastatin) advocated 
 Regional formularies statins such as the Lothian and 
Greater Glasgow formularies advocating generic 
simvastatin (40mg generic simvastatin)  
 General monitoring of prescribing, benchmarking and 
academic detailing to enhance appropriate statin 
prescribing 
2011 Regional 
(NHS 
Highland) 
 Educational initiatives encouraging the switching of 
atorvastatin to simvastatin where applicable  
2012 Regional 
(GGC) 
 Educational initiatives advocating that ezetimibe should 
only be prescribed by specialists when cholesterol 
targets are not reached on maximal tolerated statins 
2013 Regional 
(GGC) 
 Educational initiatives outlining generic simvastatin is 
considered more cost-effective than generic atorvastatin 
or other LLAs, with atorvastatin recommended as second 
choice in patients not reaching target levels on 40mg/ 
day simvastatin 
2013 Regional 
(GGC) 
 Educating physicians that pravastatin should only be 
prescribed in patients that are on other medicines that 
interact with either atorvastatin or simvastatin; otherwise 
encouraged to switch to atorvastatin and simvastatin as 
pravastatin is considered less potent  
2014 National  High dose atorvastatin (80mg) first choice for secondary 
prevention CHD 
Engineering 
2001 - 
2007 
National and 
Regional 
 ‚Better Care Better Value’ indicators to enhance the 
prescribing of low cost statins versus single sourced 
statins 
 Quality targets for statin prescribing as part of Audit 
Scotland in 2003 
 Quality and Outcome Framework targets including those 
for diabetes, hypertension, stroke and CHD 
 Therapeutic switching by Health Board pharmacists 
when working with GPs 
2012 National  Proportion of simvastatin, atorvastatin and pravastatin 
compared to total statins 
 Proportion of ezetimibe compared to total ezetimibe and 
statins  
2012 
 
Regional  An audit of existing patients receiving ezetimibe and 
ezetimibe combination products should be carried out at 
baseline and as part of routine follow-up after an 
appropriate period to reduce its use 
2012 Regional 
(GGC) 
 Screening of patients to identify those that can be 
successfully switched from ezetimibe to a statin 
 Screening of patients who can be successfully switched 
from rosuvastatin to either atorvastatin or simvastatin  
Economics 
2001 - 
2007 
National and 
Regional 
 Practice based financial incentive schemes for statins to 
encourage prescribing of generic statins especially 
simvastatin 
 Payment by result schemes around statins 
2007 Regional 
(GGC, NHS 
 Incentive schemes for ezetimibe to reduce its use 
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Highland and 
others) 
Enforcement/ 
Engineering 
2010 Regional  Ezetimibe removed from Health Board formularies 
2011 Regional  West of Scotland Cardiac Prescribing Group issued an 
action notice to NHS Scotland Boards advising them to 
disinvest completely from the prescribing of ezetimibe 
except for those patients who are intolerant of statins 
and where optimum statin prescribing has been 
unsuccessful in reducing cholesterol levels 
2013 Regional 
(GGC) 
 Rosuvastatin still on the formulary but restricted to third 
line after simvastatin and atorvastatin 
 Practices should agree a policy to reduce its use and 
screen patients to identify appropriate patients 
 
Figure 2 – Timelines for key demand side initiatives in Scotland in recent years [adapted from (37, 54, 
64, 65, 67-69)]  
 
 
 
3.4 Influence of supply- and demand-side measures on LLAs in Scotland 
In 2001, simvastatin, atorvastatin and pravastatin were the most prescribed LLAs, and combined they 
represented 85.54% of all dispensed LLAs in Scotland. They represented 5.54% of total expenditure 
on medicines in NHS Scotland and 91.32% of total LLA expenditure. By 2015, rosuvastatin had 
replaced pravastatin, and the most prescribed LLAs in terms of items dispensed were simvastatin, 
atorvastatin and rosuvastatin. Together they represented 95.19% of total LLA utilization, and 2.09% 
and 89.14% of the total NHS costs and total LLA costs respectively (Figures 3 and 4). This reflects the 
influence of ongoing efforts by the Health Boards and NHS in Scotland and others to promote 
simvastatin, and more recently atorvastatin either as first line or second line following generic 
availability and its effectiveness and safety at higher doses than simvastatin, with active switching 
encouraged to replace rosuvastatin with atorvastatin or simvastatin (Table 2, Figure 4). All three of 
these statins are perceived to have greater strength than pravastatin (Table 2).  
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Figure 3 - Total expenditure of selected lipid lowering agents between the years 2001 and 2015 by the 
Scottish NHS 
 
 
 
 
NB: The diamonds represent the year of generic availability 
 
Figure 4 - Total dispensed units (items dispensed) of selected LLAs between 2001 and 2015 
 
 
NB: The diamonds represent the year of generic availability 
 
Of the seven LLAs included in this study, four lost their patent between the years 2001 and 2015: 
atorvastatin, simvastatin, pravastatin and fluvastatin. The patents for rosuvastatin and ezetimibe 
expired in 2017 (Table 1), while the patent for the combination of ezetimibe/simvastatin will not expire 
until 2019 (Table 1). Typically, there was an expected and immediate decrease in the price of the 
generic form of LLAs once available, although not in every case (Figure 5). These price reductions led 
to an appreciable reduction in overall expenditure for that statin over time despite increasing volumes, 
as seen with simvastatin and atorvastatin (Figures 3,4, and 5), mirroring previous findings (20, 34). As 
9 
 
a result of successful measures to encourage the preferential prescribing of multiple sourced statins 
when available (Table 2, Figure 4), this national indicator for the statins was dropped in 2014 (66). 
This reflects the importance of regularly reviewing quality indicators to only concentrate on the most 
meaningful. 
 
The availability of generic presentations of simvastatin and atorvastatin, in conjunction with quality and 
efficiency prescribing measures (Table 2, Figure 3), led to an appreciable increase in their prescribing 
(Figure 4), while simultaneously reducing the expenses and prescriptions of other LLAs, in particular 
presentations that contained ezetimibe as well as rosuvastatin (Figures 3 and 4). This increase in their 
prescribing was helped by high voluntary INN prescribing in Scotland for all medicines where there are 
no concerns with generic switching (20, 34). In 2015, INN prescribing rates were 99.7% for 
atorvastatin and pravastatin and 99.1% for simvastatin, similar to other medicines in other disease 
areas in Scotland (34, 70). Simvastatin 40 mg tablets were £44.44 in 2003 per item dispensed 
reducing to £1.96 in 2015. Similar trends were seen with atorvastatin with its price dropping from 
£38.20 per item dispensed pre-patent loss to £3.15 per item dispensed in 2015, mirroring other 
generic medicines in Scotland (34, 70). These price reductions helped to bring down total expenditure 
on statins (Figure 3), with typically stable prices for patented statins (Figure 5). 
 
Figure 5 - Price per item dispensed of LLAs from 2001 to 2015 
 
 
NB: The diamonds represent the year of generic availability 
 
Between 2003 and 2011, the growth rate of atorvastatin prescriptions (Figure 3) was slowed in favor of 
appreciably cheaper (Figure 5) and perceived equally effective generic simvastatin. As soon as 
atorvastatin lost its patent, prices and expenditure fell (Figures 3 and 5) whilst utilization rose (Figure 
4). In 2001, simvastatin and atorvastatin represented 69.99% of LLA prescriptions. By 2015, this had 
increased to 89.49% of total items dispensed.  
 
The use of higher strength simvastatin (40 and 80 mg) was encouraged to reduce morbidity and 
mortality secondary to cardiovascular events (Table 2) and as part of QoF targets (20, 34), with more 
recently high strength atorvastatin advocated over simvastatin and rosuvastatin following generic 
availability. As mentioned, this is due to the better tolerability of atorvastatin compared with simvastatin 
at higher doses. These combined activities resulted in stabilization of simvastatin use in recent years, 
with the growth in the utilization of atorvastatin (Figure 4). Overall, high dose atorvastatin (20 to 80mg) 
and simvastatin (40mg and 80mg) now represent 71.3% of total items dispensed for these two statins, 
up from 17.3% in 2001 (Table 3). The percentage of high dose atorvastatin (40mg and 80mg) has also 
appreciably increased over the years as a percentage of total atorvastatin dispensed (Table 3). 
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Table 3 – Prescribing of high and low doses statins 2001 to 2015 
 
 
 
Other statins, like fluvastatin and pravastatin, are currently not recommended by the Health Boards in 
Scotland despite low individual costs. Their use has been replaced by perceived more cost-effective 
LLAs  with appreciable evidence of effectiveness in both primary and secondary prevention coupled 
with considerable evidence on safety (Figure 4).  
 
There have also been active campaigns nationally and among the Health Boards in Scotland in recent 
years to reduce potentially inappropriate prescribing of ezetimibe alone or in combination due to 
concerns about the actual impact on cardiac events in reality (Table 2) versus the proven 
effectiveness of higher doses of atorvastatin and simvastatin at considerably lower cost (Figure 5). 
This included incentive schemes to reduce ezetimibe use, removal of ezetimibe from Health Board 
NHS formularies as well as national therapeutic indicators for ezetimibe. As a consequence, the 
prescribing of ezetimibe in terms of items dispensed decreased by 72% between 2010 and the end of 
the year 2015 (Figure 6), representing saving of over £6 million in 2015.   
 
  
2015 2001
Atorvastatin (items dispensed)
10mg 322250 208809
20 and 30mg 478380 91082
40 to 80mg 836370 32591
% LD atorvastatin 19.7 62.8
% HD atorvastatin 80.3 37.2
% 40 + 80 mg vs all 51.1 9.8
Simvastatin (items dispensed) 2015 2001
10 and 20mg 970125 586013
40 and 80mg 1889792 43059
% LD simvastatin 33.9 93.2
% HD simvastatin 66.1 6.8
Overall (statins combined)
% LD statins 28.7 82.7
% HD statins 71.3 17.3
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Figure 6 – Utilisation of ezetimibe (including combinations) in NHS Scotland 2003-2015 
 
NB: Point A represents the time when ezetimibe was removed from local health board formularies in 
Scotland and Point B when national therapeutic indicators were launched for ezetimibe 
 
4. Discussion 
 
The tendency to prescribe LLA depends not only on their clinical efficacy and safety, but also 
associated costs. The loss of a patent appears to appreciably influence subsequent prescribing 
patterns not only for the particular LLA, but also the other LLAs that have similar indications as long as 
they share similar efficacy and safety profiles and are broadly seen as interchangeable. For example, 
simvastatin experienced a constant increase in volumes from 2001 to 2003 following a number of 
publications including the 4S study (17), during which time the dispensed volume increased by 56%, 
but its use accelerated further following patent loss in 2003, and by 2013 the prescription rate in terms 
of items dispensed was 2.9 times higher than seen in 2003 (Figure 4). 
 
Atorvastatin saw its increasing prescription trend slow, and latterly plateau, following the availability of 
generic simvastatin. This trend was reversed as soon as atorvastatin lost its patent in the 2012 along 
with appreciably lower prices and NHS Scotland advocating high doses statins (Table 2, Figures 3 and 
4), with prescription rates increased 10% per year on average after that. As a consequence, the 
utilisation of simvastatin was affected, and its prescription rate decreased by approximately 8% 
between 2013 and 2015. The prescribing of rosuvastatin also fell by 18.6% following the availability of 
generic atorvastatin (Figure 4). This exemplifies how generic and patented products interact with each 
other and affect the way they are prescribed.  
 
Again, multiple initiatives surrounding the 4Es appeared necessary to effect these changes in 
prescribing patterns, similar to other studies (35, 71, 72). In addition, multiple initiatives in Scotland 
had a similar influence on prescribing patterns to formal prescribing restrictions, which are not possible 
in Scotland for statins, similar to other disease areas (34, 46, 48). 
 
It is important to mention that the price of medicines does not have a direct effect on prescribed 
volumes (as prices are effectively invisible to patients); however, there is an indirect effect as price 
changes call forth educational and other initiatives on the part of the government and the local Health 
Boards (Table 2). In Scotland, the increased utilization of statins over other LLAs was assisted by the 
Quality and Outcomes Framework and SIGN guidelines, which combined recommend simvastatin at 
high doses to achieve target lipid levels (20). More recently, SIGN and other prescribing guidance 
have advocated high dose atorvastatin (80mg) for patients with established CVD. In addition, 
ambulatory physicians in Scotland received financial incentives when high risk patients reach specific 
target lipid levels (20). As seen, rosuvastatin, which is considered an effective statin (73), has not seen 
this increase in prescription volumes in NHS Scotland, perhaps due to the fact that it was still on 
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patent during the study period and generic atorvastatin was available with similar effectiveness at 
considerably lower costs (Figures 3 and 5), resulting in successful switching programmes and falling 
prescribing (Table 2, Figure 4). Similarly, the availability of generic simvastatin and atorvastatin, 
coupled with the lack of outcome data, resulted in active educational and other activities to limit 
inappropriate prescribing of appreciably more expensive ezetimibe alone or in combination in recent 
years (Figures 4 and 6).   
 
As a result, the multiple demand side measures introduced for the various LLAs over time in Scotland 
(Table 2, Figure 2) appear to have successfully moderated or reduced the prescribing of LLAs with 
higher costs but no perceived additional benefits (Figures 3 to 5), providing exemplars to other 
countries with limited demand side measures to encourage the prescribing of patented medicines with 
limited additional benefits (30, 34, 35, 74). At the same time, the quality of prescribing has been 
improved with the advocacy of higher statin doses and limiting inappropriate prescribing of ezetimibe. 
 
Patented medicines have an important impact on the Scottish NHS medicines’ budget. In 2005, the 
use of patented LLAs represented over £18.1 million, but by 2015 this had decreased to £10 million, 
nevertheless still representing 42.1% of the total budget for LLAs. As older statins lose their patent 
and become cheaper, moving away from patented formulations in favor of generic presentations or 
other statins with similar efficacy and safety profiles, is now a reality that it is possible to achieve. This 
can contribute to substantial additional savings within the NHS system despite increasing volumes and 
doses without endangering the health of the population. These savings can be used to fund increased 
use of medicines in other disease areas as a result of ageing populations, as well as new higher 
priced but valued medicines, within a universal healthcare system with finite resources. Ongoing 
strategies will intensify to help further increase the prescribing of LLAs without increasing budgets at a 
time of increasing pressure on resources.  We will be researching their impact in the future. 
 
We are aware of a number of limitations. The major ones are the fact that we cannot link prescribing of 
statins to any diagnoses or outcomes with this dataset. In addition, there can be differences between 
prescribing and dispensing data. We also could not measure adherence rates, which is a key 
consideration with statin prescribing (75-78). This is particularly important with higher dose statins and 
the potential for increasing side-effects, which will be the subject of future research. Lastly, as 
mentioned, the use of items dispensed rather than DDDs will mean that the overall increase in 
utilisation will be appreciably lower than if DDDs has been used, especially when coupled with the 
increasing length of prescriptions in recent years to reduce physician workloads and increased 
prescribing of higher strength statins. Never-the-less, we believe our findings are robust, providing 
guidance for the future.   
 
5. Conclusion 
 
The instigation of multiple supply- and demand-side measures in Scotland in recent years have 
resulted in increased prescribing of generic statins once available versus patented statins, leading to 
appreciably reduced expenditire between 2001 and 2015 despite over 400% increase in utilisation 
during this period. Concurrent with this, there has been increasing prescribing of higher dose statins to 
improve outcomes whilst limiting inappropriate prescribing of ezetimibe alone or in combination with no 
proven effect to reduce cardiac events. This includes advocating 80mg atorvastatin in revent years for 
secondary prevention. Consequently, we believe the multiple activities in Scotland and their outcome 
can be an exemplar for other countries seeking to enhance their quality and efficiency of prescribing. 
We will now be researching statin adherence in more detail combined with ongoing initiatives to 
enhance high strength prescribing. 
 
6. Key issues 
 
 Over half the adults in the UK have hypercholesterolaemia, which increasingly needs treating with 
high dose statins to help prevent future coronary events 
 
 This can be financed through the instigation of multiple initiatives to increase the prescribing of low 
cost generic statins at the expense of appreciably more expensive patented statins without 
compromising care, In addition, encourage the prescribing of higher strength statins and reduce 
inappropriate prescribing of ezetimibe  
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 Multiple regional and national initiatives in Scotland including physician education, guidelines, 
prescribing targets and financial incentives appreciably increased the prescribing of low dose 
statins and limited ezetimibe prescibing. As a result, whilst items dispensed for lipid lowering 
agents increased by 412% between 2001 and 2015, there was a 50% reduction in their 
expenditure 
 
 The many measures resulted in appreciably increased prescribing of high dose statins over the 
years (representing 71% of items dispensed in 2015) and reduced inappropriate prescribing of 
ezetimibe (items dispensed reduced by 72% between 2010 and 2015) 
 
 These initiatives will continue given increasing pressure on budgets in Scotland including the 
medicine’s budget 
   
7. Expert Commentary 
 
There are continuing pressures on resources in European countries with ageing populations and 
continued unmet needs. As a result, ongoing supply- and demand-side measures are needed to 
enhance both the quality and efficiency of prescribing to maintain universal and comprehensive 
healthcare where this exists. This is particulalry the case for LLAs given increasing rates of 
hypercholesterolaemia across Europe including Scotland, as well as the need to prescribe higher 
statin doses to reduce the rate of future cardiac events. Scotland has introduced multiple measures 
before and during the availability of generic statins, as well as initiatives to improve the quality of 
prescribing, to achieve these aims.  
 
These multiple measures have resulted in high rates of INN prescribing for the statins (99%) as well as 
preferential prescribing of generic versus patented statins. In addition, increased prescribing of higher 
dose statins, which now represent 71% of all statins dispensed in Scotland. Multiple measures have 
also reduced inappropriate prescribing of ezetimibe, with a 72% reduction in items dispensed between 
2010 and 2015. Overall, there was a 50% reduction in expenditure on LLAs in Scotland between 2001 
and 2015 despite a 412% increase in the number of items dispensed during this period. These 
measures are ongoing to further improve the quality and efficiency of LLA prescribing in Scotland, 
providing examplars to other European countries faced with similar issues. 
   
8. Five-year review 
 
It is likely that generic atorvastatin will dominate statin prescribing in the coming years at high doses. 
The availability of generic rosuvastatin will help further ease expenditure on LLAs, although it is 
unlikely the prescribing of rosuvatstatin will increase significantly over the coming years at the expense 
of atorvastatin. However, it is likely we will see increased prescribing of appreciably more expensive 
PCSK9 inhibitors for patients who have familial hypercholesterolaemia with uncontrolled high lipid 
levels or those with mixed dyslipidaemia not controlled wtih low cost statins. As a result, while we are 
likely to see increased prescribing of LLAs including the PCSK9 inhibitors, it is unlikely we will see 
apperciable falls in expenditure compared with 2015 levels.  
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